Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells
© He et al.; licensee BioMed Central Ltd. 2012
Received: 15 July 2011
Accepted: 21 April 2012
Published: 30 April 2012
Non–small cell lung cancer is associated with high expression of multidrug resistance (MDR) proteins and low production of reactive oxygen species (ROS). Coptis extract (COP), a Chinese medicinal herb, and its major constituent, berberine (BER), have anticancer properties. This study aims to investigate the effects of COP and BER combined with chemotherapeutic agents, including fluorouracil (5-FU), camptothecin (CPT), and paclitaxel (TAX), on cell proliferation, ROS production, and MDR in A549 human non-small cell lung cancer cells.
A549 cells were treated with different doses of COP and BER, combined with 5-FU, CPT, and TAX. Cell viability was measured by an XTT (2,3-bis-(2-methoxy-4- nitro-5-sulfophenyl)-2 H-tetrazolium-5-carboxanilide) assay. Intracellular ROS levels were determined by measuring the oxidative conversion of cell permeable 2′,7′-dichlorofluorescein diacetate to fluorescent dichlorofluorescein. MDR of A549 cells was assessed by rhodamine 123 retention assay.
Both COP and BER significantly inhibited A549 cell growth in a dose-dependent manner. Combinations of COP or BER with chemotherapeutic agents (5-FU, CPT, and TAX) exhibited a stronger inhibitory effect on A549 cell growth. In addition, COP and BER increased ROS production and reduced MDR in A549 cells.
As potential adjuvants to chemotherapy for non–small cell lung cancer, COP and BER increase ROS production, reduce MDR, and enhance the inhibitory effects of chemotherapeutic agents on A549 cell growth.
The herb Coptis (COP) is used to treat “damp heat” syndrome in Chinese medicine . Its major constituent is berberine (BER), an isoquinoline alkaloid . The anticancer effects of COP and BER on both hematological and nonhematological cancers have been well documented . Since 2000, experimental studies have confirmed the cytotoxicity of BER in various cancer cell lines, including YES (esophageal carcinoma) , HK1 (nasopharyngeal carcinoma) , HeLa (cervical carcinoma) , HepG2 (hepatocellular carcinoma) . Our previous studies [9, 10] have also shown that COP inhibits the growth of breast cancer cells.
Non–small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers, and only responds to 15%–25% single agents and 25%–40% combined chemotherapy . NSCLC is typically resistant to apoptosis induced by standard chemotherapy, which causes excessive levels of reactive oxygen species (ROS), leading to impaired intracellular ionic homeostasis by damaging cellular macromolecules and inducing apoptosis . Mitochondrial ROS production is crucial to NSCLC apoptosis induced anticancer agents . In addition to ROS, multidrug-resistance (MDR) proteins are intrinsically expressed and functionally active in NSCLC cells . Several adjuvants to chemotherapy for NSCLC are being tested, with promising results, including the antagonists of EGFR and COX-2 [15–17].
This study aims to investigate the effects of COP and BER on ROS production and MDR, and the effects of combinations of COP or BER with chemotherapeutic agents, including fluorouracil (5-FU), camptothecin (CPT), and paclitaxel (TAX) on A549 human cancer cells, which are derived from NSCLC .
A powder form of COP extract was made from Coptis japonica (Mayway Corporation, Oakland, CA, USA) by boiling the plant in water and spray drying. A solution of COP was prepared as previously described . BER, 5-FU, CPT, and TAX were purchased from Sigma-Aldrich (USA). BER, 5-FU, and CPT were dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich, USA), and TAX was dissolved in 100% ethanol (Fisher Scientific, USA). The final concentrations of DMSO and ethanol in the medium were less than 0.1%.
The A549 cell line (ATCC CCL-185) was purchased from ATCC (Manassas, VA, USA). The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 100 U/mL penicillin, 100 g/mL streptomycin, and 10% inactivated fetal calf serum (FBS, HyClone, South Logan, UT, USA). The cells were incubated at 37°C under a humidified atmosphere of 95% air and 5% CO2. Cells were subcultured twice weekly.
Cell viability assay
Measurement of reactive oxygen species
Intracellular ROS levels were determined by measuring the oxidative conversion of cell permeable 2′, 7′ dichlorofluorescein diacetate (DCFH-DA; Sigma-Aldrich, USA) to fluorescent dichlorofluorescein (DCF) . Cells were plated in 24-well culture plates (2 × 105 cells/well) and incubated with drugs for 24 h. The cells were then washed with d-Hank’s solution (Invitrogen, USA) and incubated with 10 μM DCFH-DA in phenol-red-free MEM medium (Invitrogen, USA) at 37°C for 15 min. DCF fluorescence distribution was measured in a microplate reader (PerkinElmer, Waltham, MA, USA) at an excitation wavelength of 488 nm and emission wavelength of 535 nm. The fluorescence intensity was normalized according to the number of cells.
Rhodamine 123 retention assay
Rhodamine 123 retention was measured to evaluate the multidrug resistance (MDR) of cancer cells [19, 20]. Briefly, 24-well plates with 2 × 105 cells/well were treated with low or high doses of COP (low dose: 1.6 μg/mL, high dose: 6.4 μg/mL) and BER (low dose: 0.5 μg/mL, high dose: 4 μg/mL) for 24 h. The cells were then incubated in phenol-red-free MEM containing 10 μg/mL rhodamine 123 (Sigma-Aldrich, USA) and 2% FBS for 20 min at 37°C. After incubation, the cell monolayers were washed 3 times with ice-cold phosphate buffered saline (PBS), trypsinized, and suspended in MEM medium containing 2% FBS. The cell suspension was transferred to a 96-well plate and measured in a microplate reader (PerkinElmer,Waltham, MA, USA) at an excitation wavelength of 485 nm and emission wavelength of 535 nm. The fluorescence intensity was normalized by the number of cells. All experiments were performed in quadruplicate.
The data were expressed as means ± standard deviations (SD). A one-way ANOVA was performed to test the difference among groups of controls, individual agents, and combinations of agents using Graph Pad Prism 4 software (San Diego, CA, USA). Newman-Keuls tests were used for multiple comparisons. The software did not provide exact P values for ANOVA; thus, no exact P values are reported. The results with P < 0.05 were considered statistically significant. Each experiment was repeated at least 3 times.
A549 cell growth
Production of reactive oxygen species in A549 cells
Our results show that both COP and BER significantly increased ROS levels in A549 cells, in a dose-dependent manner, and enhanced the inhibitory effect of chemotherapeutic drugs on A549 cells. The present study agrees with previous findings that ROS production is increased in cancer cells , which sensitizes the cancer cells to drugs [13, 22] and to radiotherapy . It has been reported  that BER enhances the anticancer effect of irradiation by increasing ROS production in human hepatoma cells.
Inhibition of MDR in A549 cells
NSCLC is extremely difficult to treat because of its low therapeutic and long-term survival rates . This study demonstrates that a combination of COP or its major constituent BER with chemotherapeutic drugs including 5-FU, CPT, and TAX exhibits a stronger inhibitory effect on the growth of A549 human lung cancer cells than any individual treatment. These findings suggest a potential use of COP and BER in the adjuvant treatment of NSCLC.
ROS levels are elevated in cells exposed to various stressors, including anticancer drugs, leading to apoptosis by stimulating pro-apoptotic signaling molecules (e.g., P53, MAPK, etc.) . Some studies [13, 22] have shown that increasing the production of ROS may sensitize cancer cells to drugs. Our results show that both COP and BER significantly increase ROS levels in A549 cancer cells in a dose-dependent manner, which is consistent with the enhanced inhibitory effect of chemotherapeutic drugs combined with COP or BER on A549 cancer cells.
Multiple drug resistance (MDR) is still the major cause of cancer therapy failure. MDR involves the overexpression of membrane P-glycoprotein (Pgp) and a reduced ability to accumulate and retain therapeutic drugs because of the energy-dependent Pgp efflux pump. Almost all NSCLC display intrinsic MDR, generally limiting the chance of successful chemotherapy [23, 24]; this is a key reason why lung cancer is currently a leading cause of cancer death worldwide. Combined therapy with cytotoxic drugs and MDR modulators is a promising strategy for overcoming clinical MDR. Some traditional herbal medicines, such as Coptis, Poria, and Zizyphi fructushave been reported to reverse MDR . Our results show that COP and BER at low and high doses significantly increase the retention of Rhodamine 123 dye, suggesting an inhibition of P-gp and/or MRP efflux activity in the A549 cancer cells. In turn, decreased MDR activity may contribute to the inhibitory effects of chemotherapeutic drugs in conjunction with COP and BER on A549 cancer cells. However, Lin et al. reported  that berberine up-regulated MDR transporter pgp-170 expression and reduced the response to paclitaxel in digestive track cancer cells. We assume that different types of cell lines may respond differently to berberine at certain concentrations.
The anticancer effects of COP and BER may involve other pathways. Both 5-FU and CPT inhibit cellular DNA replication [26, 27], and TAX inhibits cell division by stabilizing microtubules, triggering death of rapidly dividing cancerous cells . Some studies [29, 30] have indicated that COP and BER exhibit anticancer effects by inhibiting the activity of DNA topoisomerases and protein kinase C. Our previous study  showed that COP and BER markedly inhibit cell proliferation and induce apoptotic cell death of MCF-7 cells through up-regulation of interferon-β, an important cytokine that regulates cell growth and death. COP and BER also enhance the anticancer effect of estrogen receptor antagonists, including tamoxifen and fulvestrant, likely by regulating multiple cancer-related genes, e.g., EGFR, HER2, bcl-2, COX-2, and p21. In this study, we observed some differences in efficacy between COP and BER. It may be that there were components in COP other than BER that contributed to its anticancer effect in agreement with our previous studies [9, 10]. Further studies are required to discover the pathways targeted by COP and BER.
This study demonstrated that combinations of COP or BER with chemotherapeutic drugs (5-FU, CPT, and TAX) are more effective in inhibiting the growth of A549 cells than that of any single-agent therapy, possibly due to increased production of ROS and reduce MDR.
Non–small cell lung cancer
Reactive oxygen species
We thank Sarah A. Brigandi, Marilla C. Pender-Cudlip, and Erin D. Gleason for assistance in manuscript preparation. This work was partially supported by the NIH grant CA113605 (to JK) and the National Natural Science Foundation of China (30672741 to KZ). We also thank Dr. Qingwen Zhang from the University of Macau for providing Coptis extract.
- Yin J, Zhang H, Ye J: Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets. 2008, 8: 99-111. 10.2174/187153008784534330.PubMed CentralView ArticlePubMed
- Chang YC, Chen LY: Determination of berberine in coptis. Yao Xue Xue Bao. 1962, 13: 418-423.PubMed
- Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y: Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009, 126: 5-17. 10.1016/j.jep.2009.08.009.View ArticlePubMed
- Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M: Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 2000, 148: 19-25. 10.1016/S0304-3835(99)00264-5.View ArticlePubMed
- Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y: Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8 F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine. J Biol Chem. 2009, 284: 27456-27466. 10.1074/jbc.M109.033795.PubMed CentralView ArticlePubMed
- Jantova S, Cipak L, Cernakova M, Kost’alova D: Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol. 2003, 55: 1143-1149.View ArticlePubMed
- Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW: Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010, 111: 1426-1436. 10.1002/jcb.22869.View ArticlePubMed
- Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer I. 1973, 51 (5): 1409-1416.
- Kang JX, Liu J, Wang J, He C, Li FP: The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis. 2005, 26: 1934-1939. 10.1093/carcin/bgi154.View ArticlePubMed
- Liu J, He C, Zhou K, Wang J, Kang JX: Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem Biophys Res Commun. 2009, 378: 174-178. 10.1016/j.bbrc.2008.10.169.PubMed CentralView ArticlePubMed
- Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. J Am Med Assoc. 2004, 292: 470-484. 10.1001/jama.292.4.470.View Article
- Simon HU, Haj-Yehia A, Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000, 5: 415-418. 10.1023/A:1009616228304.View ArticlePubMed
- Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castera L, Cuevas C, Formstecher P, Joseph B, Kroemer G, Bailly C, Marchetti P: Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene. 2008, 27: 1981-1992. 10.1038/sj.onc.1210833.View ArticlePubMed
- Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001, 7: 1798-1804.PubMed
- Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Brit Med J. 1995, 311: 899-909.
- Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol. 2004, 22: 777-784. 10.1200/JCO.2004.08.001.View ArticlePubMed
- Brown JR, DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004, 10: 4266s-4269s. 10.1158/1078-0432.CCR-040014.View ArticlePubMed
- Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer I. 1973, 51 (5): 1417-1423.
- Fontaine M, Elmquist WF, Miller DW: Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 1996, 59: 1521-1531. 10.1016/0024-3205(96)00483-3.View ArticlePubMed
- Brouty-Boye D, Kolonias D, Wu CJ, Savaraj N, Lampidis TJ: Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res. 1995, 55: 1633-1638.PubMed
- Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995, 18: 775-794. 10.1016/0891-5849(94)00198-S.View ArticlePubMed
- Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004, 7: 97-110. 10.1016/j.drup.2004.01.004.View ArticlePubMed
- Hur JM, Hyun MS, Lim SY, Lee WY, Kim D: The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem. 2009, 107: 955-964. 10.1002/jcb.22198.View ArticlePubMed
- Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L: Berberine Inhibits Human Hepatoma Cell Invasion without Cytotoxicity in Healthy Hepatocytes. PLoS One. 2011, 6 (6): e21416-10.1371/journal.pone.0021416.PubMed CentralView ArticlePubMed
- Benhar M, Engelberg D, Levitzki A: ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002, 3: 420-425. 10.1093/embo-reports/kvf094.PubMed CentralView ArticlePubMed
- Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3 (5): 330-338. 10.1038/nrc1074.View ArticlePubMed
- Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AI, Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc. 1966, 88 (16): 3888-3890. 10.1021/ja00968a057.View Article
- Wani M, Taylor H, Wall M, Coggon P, McPhail A: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971, 93 (9): 2325-2327. 10.1021/ja00738a045.View ArticlePubMed
- Kim SA, Kwon Y, Kim JH, Muller MT, Chung IK: Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Biochemistry. 1998, 37: 16316-16324. 10.1021/bi9810961.View ArticlePubMed
- Lin TH, Kuo HC, Chou FP, Lu FJ: Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer. 2008, 8: 58-10.1186/1471-2407-8-58.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.